Cardea Bio and Nanosens Innovations merger-acquisition finalized

Cardea Bio (formerly: Nanomedical Diagnostics) and Nanosens Innovations have joined forces to accelerate the development of the Genome Sensor: the world's first DNA search engine that runs on CRISPR-Chip technology.

Cardea has announced the finalization of their merger-acquisition of Nanosens Innovations, the creators of CRISPR-Chip. Cardea first came out with the news of the proposed merger in September, along with the announcement of their Early Access Program for the Genome Sensor. Built with CRISPR-Chip technology, the Genome Sensor is the world’s first DNA search engine. It can google genomes to detect genetic mutations and variations.

Merging the two companies allows the power of Nanosens’ CRISPR-Chip technology to be combined with Cardea’s graphene biosensor infrastructure. This enables Cardea to build an advanced DNA version of its biology-based transistors which would otherwise normally work with proteins. Via the Powered by Cardea strategy, a series of new CRISPR-Chip DNA-focused products will be developed and marketed via Cardea’s partnerships with large companies in different markets.

We are thrilled to announce that both companies’ Board of Directors and Shareholders have strongly supported the merger by voting yes to combining the two companies. I’d like to thank everyone who has made this possible. We here at Cardea are excited to expand our team of talents with the talents from Nanosens, says Cardea’s CEO, Michael Heltzen. 

Nanosens will continue as a Cardea brand for the Genome Sensor and other tools made for the research market.

With Nanosens as our internal Innovation Partner, and a handful of external Innovation Partnerships soon to be signed, we are ready to take in the investments we have been offered and scale up Cardea. This will take us to the next level on our venture to build the biology-based transistor company that allows for people to connect computers directly with biology, continues Heltzen.